OncLive SOSS

My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer - Episode 6

Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

May 1, 2023

Andrew J. Armstrong, MD, Matthew Manning, MD

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

EP. 2: Approved Treatment Options for Patients with mCRPC

EP. 3: Patient Profile: A 78-Year-Old Man with mCRPC

EP. 4: Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

EP. 5: Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

EP. 6: Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

EP. 7: Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

EP. 8: Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

EP. 9: Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

EP. 10: Closing Thoughts on the Future of mCRPC Treatment

x